Inogen, Inc (NASDAQ:INGN) Director Raymond Huggenberger sold 14,000 shares of the stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $102.30, for a total value of $1,432,200.00. Following the transaction, the director now owns 7,808 shares in the company, valued at approximately $798,758.40. The sale was disclosed in a document filed with the SEC, which is available through this link.

Raymond Huggenberger also recently made the following trade(s):

  • On Tuesday, August 15th, Raymond Huggenberger sold 14,000 shares of Inogen stock. The shares were sold at an average price of $91.67, for a total value of $1,283,380.00.
  • On Friday, July 14th, Raymond Huggenberger sold 14,000 shares of Inogen stock. The shares were sold at an average price of $92.96, for a total value of $1,301,440.00.

Inogen, Inc (NASDAQ INGN) opened at 103.58 on Thursday. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of 89.91 and a beta of 1.02. The stock’s 50 day moving average price is $96.45 and its 200-day moving average price is $88.05. Inogen, Inc has a 12 month low of $50.24 and a 12 month high of $105.35.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.10. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The firm had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. During the same quarter in the prior year, the company posted $0.25 earnings per share. Inogen’s quarterly revenue was up 17.4% on a year-over-year basis. Equities research analysts predict that Inogen, Inc will post $1.21 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Raymond Huggenberger Sells 14,000 Shares of Inogen, Inc (INGN) Stock” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/21/raymond-huggenberger-sells-14000-shares-of-inogen-inc-ingn-stock.html.

INGN has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Needham & Company LLC decreased their target price on Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a research report on Thursday, June 8th. J P Morgan Chase & Co increased their target price on Inogen to $102.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Piper Jaffray Companies reiterated a “hold” rating and set a $90.00 target price on shares of Inogen in a research report on Tuesday, September 12th. Finally, BidaskClub upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 8th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Inogen has an average rating of “Buy” and a consensus price target of $91.33.

A number of hedge funds have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new position in Inogen during the second quarter worth $442,000. Koch Industries Inc. grew its holdings in Inogen by 19,485.8% during the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after acquiring an additional 653,747 shares during the period. Verition Fund Management LLC acquired a new position in Inogen during the second quarter worth $280,000. Piedmont Investment Advisors LLC acquired a new position in Inogen during the second quarter worth $336,000. Finally, Ameritas Investment Partners Inc. grew its holdings in Inogen by 6.1% during the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 86 shares during the period.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.